To access this element change to forms mode OFF
Grant Award View - GA40783
PICCOG: PARP and Immune Checkpoint inhibitor COmbination for relapsed...
GA ID:
GA40783
Agency:
Department of Health and Aged Care
Approval Date:
29-Mar-2019
Publish Date:
26-Apr-2019
Category:
Medical Research
Grant Term:
1-Apr-2019 to 31-Mar-2024
Value (AUD):
$1,391,472.20
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 18/19 1.1 Health and Medical Research
Grant Program:
2018_MRFF Rare Cancers Rare Diseases, Unmet Need_commencing_2018
Grant Activity:
PICCOG: PARP and Immune Checkpoint inhibitor COmbination for relapsed IDH-mutant high-grade Glioma
Purpose:
There are no effective treatments for patients with relapsed glioma. In the subset of patients with isocitrate dehydrogenase (IDH)-mutant glioma, there is promising biologic rationale for, and potential synergy, combining rucaparib (which inhibits DNA repair) and nivolumab (which augments the anti-cancer immune response). This combination has been previously reported to be safe. This study will test the effectiveness of rucaparib and nivolumab against relapsed IDH-mutant glioma.
GO ID:
GO Title:
Medical Research Future Fund Clinical Trials Activity – Rare Cancers, Rare Diseases and Unmet Need Grant Opportunity
Internal Reference ID:
MRF1170139
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Sydney
Recipient ABN:
15 211 513 464
Grant Recipient Location
Suburb:
Camperdown
Town/City:
Camperdown
Postcode:
2050
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW
Postcode:
Country:
AUSTRALIA